

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
COATES et al. : Examiner: F. Krass  
Serial No.: 07/835,964 : Group Art Unit: 1614  
Filed: February 20, 1992 :

For: 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES

AMENDMENT

Assistant Commissioner for Patents  
Washington, DC 20231

SIR:

In response to the Office Action of August 12, 1999, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 57-58.

Please amend claims 25, 27-29, 33, 34, 37-39, 43, 45-48 and 50 as follows:

1 ~~25~~. (Amended Thrice) A method for treating a human suffering from HIV infection comprising administering to said [mammal] human a pharmaceutical composition comprising: a compound which is [the compound (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one] (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof, another agent having antiviral activity, and a pharmaceutically acceptable carrier, and

[wherein said pharmaceutical composition further comprises another agent having antiviral activity, and]

wherein the amount of the (+)-enantiomer of [corresponding to] said compound or of said pharmaceutically acceptable salt [is] present in said composition is no more than 5% w/w, relative to the combined weight of the (-) and (+)-enantiomers thereof.

Claim 27, line 1: After "compound" insert -- or pharmaceutically acceptable salt --.

Claim 28, line 1: After "compound" insert -- or pharmaceutically acceptable salt --.

Claim 29, line 1: After "compound" insert -- or pharmaceutically acceptable salt --.